Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre-Emmanuel Colombo

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
International Journal of Oncology|May 20, 2021
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survivalMaëva Chauvin, Véronique Garambois, Sylvie Choblet, et al.
Cancers|April 3, 2021
Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC StudyMartinez Alejandra, Witold Gertych, Christophe Pomel, et al.
Oncotarget|September 13, 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsGaëlle Thomas, Thierry Chardès, Nadège Gaborit, et al.
Mabs|April 20, 2021
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer modelsEmilia Rabia, Véronique Garambois, Julie Hubert, et al.
Clinics and Research in Hepatology and Gastroenterology|September 24, 2019
Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patientsRegis Souche, Antoine Coignac, Marie Dupuy, et al.
Cancer Letters|June 24, 2018
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancerCharline Ogier, Pierre-Emmanuel Colombo, Corinne Bousquet, et al.
Frontiers in Oncology|March 31, 2022
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry StudyMorgan Michalet, Karl Bordeau, Marie Cantaloube, et al.
Cancers|October 16, 2024
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of SurgeryGilles Houvenaeghel, Jean-Marc Classe, Marie-Pierre Chauvet, et al.
Oncotarget|January 27, 2018
The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathwayEmilie Laprevotte, Stéphanie Cochaud, Stanislas du Manoir, et al.
Theranostics|November 28, 2022
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastasesAmbre Giguelay, Evgenia Turtoi, Lakhdar Khelaf, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
International Journal of Oncology|May 20, 2021
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survivalMaëva Chauvin, Véronique Garambois, Sylvie Choblet, et al.
Cancers|April 3, 2021
Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC StudyMartinez Alejandra, Witold Gertych, Christophe Pomel, et al.
Oncotarget|September 13, 2014
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsGaëlle Thomas, Thierry Chardès, Nadège Gaborit, et al.
Mabs|April 20, 2021
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer modelsEmilia Rabia, Véronique Garambois, Julie Hubert, et al.
Clinics and Research in Hepatology and Gastroenterology|September 24, 2019
Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patientsRegis Souche, Antoine Coignac, Marie Dupuy, et al.
Cancer Letters|June 24, 2018
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancerCharline Ogier, Pierre-Emmanuel Colombo, Corinne Bousquet, et al.
Frontiers in Oncology|March 31, 2022
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry StudyMorgan Michalet, Karl Bordeau, Marie Cantaloube, et al.
Cancers|October 16, 2024
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of SurgeryGilles Houvenaeghel, Jean-Marc Classe, Marie-Pierre Chauvet, et al.
Oncotarget|January 27, 2018
The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathwayEmilie Laprevotte, Stéphanie Cochaud, Stanislas du Manoir, et al.
Theranostics|November 28, 2022
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastasesAmbre Giguelay, Evgenia Turtoi, Lakhdar Khelaf, et al.
Pageof 9